Extended single-dose toxicity study of [(211)At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer

OBJECTIVE: Astatine ((211)At) is a promising alpha emitter as an alternative to iodine ((131)I). We are preparing the first-in-human (FIH) clinical trial of targeted alpha therapy for differentiated thyroid cancer in consultation with Pharmaceuticals and Medical Devices Agency. Here, we performed an...

Descripción completa

Detalles Bibliográficos
Autores principales: Watabe, Tadashi, Kaneda-Nakashima, Kazuko, Ooe, Kazuhiro, Liu, Yuwei, Kurimoto, Kenta, Murai, Takashi, Shidahara, Yuka, Okuma, Kenji, Takeuchi, Masanori, Nishide, Masayuki, Toyoshima, Atsushi, Shinohara, Atsushi, Shirakami, Yoshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134311/
https://www.ncbi.nlm.nih.gov/pubmed/33871803
http://dx.doi.org/10.1007/s12149-021-01612-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134311/
https://www.ncbi.nlm.nih.gov/pubmed/33871803
http://dx.doi.org/10.1007/s12149-021-01612-9

Ejemplares similares